Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | UGT1A1 | P22309 | 3/20 | 0.81 |
| ▸ | MLNR | O43193 | 1/20 | 0.81 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.81 |
| ▸ | SLCO2B1 | O94956 | 1/20 | 0.81 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.81 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.81 |
| ▸ | CCKAR | P32238 | 1/20 | 0.81 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.81 |
| ▸ | GHSR | Q92847 | 1/20 | 0.81 |
| ▸ | SLCO1B3 | Q9NPD5 | 1/20 | 0.81 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.81 |
| ▸ | SLCO1B1 | Q9Y6L6 | 1/20 | 0.81 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.63 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.58 |
| ▸ | CTSD | P07339 | 3/20 | 0.58 |
| ▸ | PSEN1 | P49768 | 7/20 | 0.40 |
| ▸ | PSEN2 | P49810 | 7/20 | 0.40 |
| ▸ | APH1B | Q8WW43 | 7/20 | 0.40 |
| ▸ | NCSTN | Q92542 | 7/20 | 0.40 |
| ▸ | APH1A | Q96BI3 | 7/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL6668 | 0.99 | UGT1A1 (0.80) | UGT1A1MLNRNR1I2SLCO2B1ABCB11 | |
| SCHEMBL13315150 | 0.95 | UGT1A1 (0.74) | UGT1A1MLNRNR1I2SLCO2B1ABCB11 | |
| SCHEMBL8232164 | 0.92 | UGT1A1 (0.69) | UGT1A1MLNRNR1I2SLCO2B1ABCB11 | |
| SCHEMBL16250687 | 0.90 | UGT1A1 (0.67) | UGT1A1MLNRNR1I2SLCO2B1ABCB11 | |
| SCHEMBL7404665 | 0.90 | UGT1A1 (0.66) | UGT1A1MLNRNR1I2SLCO2B1ABCB11 | |
| SCHEMBL7404668 | 0.90 | UGT1A1 (0.66) | UGT1A1MLNRNR1I2SLCO2B1ABCB11 | |
| SCHEMBL7547851 | 0.90 | UGT1A1 (0.65) | UGT1A1MLNRNR1I2SLCO2B1ABCB11 | |
| Atazanavir SCHEMBL20629937 | 0.90 | UGT1A1 (1.00) | UGT1A1MLNRNR1I2SLCO2B1ABCB11 | |
| Atazanavir SCHEMBL22847477 | 0.90 | UGT1A1 (1.00) | UGT1A1MLNRNR1I2SLCO2B1ABCB11 | |
| Atazanavir SCHEMBL7993264 | 0.90 | UGT1A1 (1.00) | UGT1A1MLNRNR1I2SLCO2B1ABCB11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140343290-A1 | PROCESS FOR THE PREPARATION OF ATAZANAVIR OR ITS BISULFATE SALT | RANBAXY LABORATORIES LIMITED (IN) | 2014-11-20 | — | — | US | disclosed |
| US-20140343290-A1 | PROCESS FOR THE PREPARATION OF ATAZANAVIR OR ITS BISULFATE SALT | RANBAXY LABORATORIES LIMITED (IN) | 2014-11-20 | — | — | US | disclosed |
| WO-2013014633-A1 | PROCESS FOR PREPARATION OF ATAZANAVIR OR ITS BISULFATE SALT | RANBAXY LABORATORIES LIMITED (IN) | 2013-01-31 | — | — | WO | disclosed |
| WO-2013014633-A1 | PROCESS FOR PREPARATION OF ATAZANAVIR OR ITS BISULFATE SALT | RANBAXY LABORATORIES LIMITED (IN) | 2013-01-31 | — | — | WO | disclosed |
| EP-0900210-B1 | ANTIVIRALLY ACTIVE HETEROCYCLIC AZAHEXANE DERIVATIVES | NOVARTIS AG (CH) | 2005-02-09 | — | — | EP | disclosed |
| US-6300519-B1 | REACTING HYDRAZINE DERIVATIVE WITH EPOXIDE COMPOUND | NOVARTIS FINANCE CORPORATION | 2001-10-09 | — | — | US | disclosed |
| US-6166004-A | Combinations of HIV protease inhibitors with reverse transcriptase inhibitors | NOVARTIS FINANCE CORPORATION (US) | 2000-12-26 | — | — | US | disclosed |
| US-6110946-A | AN ENZYME INHIBITORS OF RETROVIRAL ASPARTATE PROTEASE FOR THE TREATMENT OF AIDS | NOVARTIS FINANCE CORPORATION (US) | 2000-08-29 | — | — | US | disclosed |
| EP-0900210-A1 | ANTIVIRALLY ACTIVE HETEROCYCLIC AZAHEXANE DERIVATIVES | Novartis AG (CH) | 1999-03-10 | — | — | EP | disclosed |
| US-5849911-A | Antivirally active heterocyclic azahexane derivatives | NOVARTIS FINANCE CORPORATION (US) | 1998-12-15 | — | — | US | disclosed |
| WO-1997040029-A1 | ANTIVIRALLY ACTIVE HETEROCYCLIC AZAHEXANE DERIVATIVES | NOVARTIS AG (CH) | 1997-10-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140343290-A1 | PROCESS FOR THE PREPARATION OF ATAZANAVIR OR ITS BISULFATE SALT | DNPEP, NSUN2, JMJD7 | UGT1A1 1373/4885MLNR 3847/4885NR1I2 2588/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.